122 related articles for article (PubMed ID: 19827751)
1. New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms.
Bruno O; Romussi A; Spallarossa A; Brullo C; Schenone S; Bondavalli F; Vanthuyne N; Roussel C
J Med Chem; 2009 Nov; 52(21):6546-57. PubMed ID: 19827751
[TBL] [Abstract][Full Text] [Related]
2. Identification of PDE4B Over 4D subtype-selective inhibitors revealing an unprecedented binding mode.
Kranz M; Wall M; Evans B; Miah A; Ballantine S; Delves C; Dombroski B; Gross J; Schneck J; Villa JP; Neu M; Somers DO
Bioorg Med Chem; 2009 Jul; 17(14):5336-41. PubMed ID: 19525117
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, biological activities and pharmacokinetic properties of new fluorinated derivatives of selective PDE4D inhibitors.
Brullo C; Massa M; Villa C; Ricciarelli R; Rivera D; Pronzato MA; Fedele E; Barocelli E; Bertoni S; Flammini L; Bruno O
Bioorg Med Chem; 2015 Jul; 23(13):3426-35. PubMed ID: 25936260
[TBL] [Abstract][Full Text] [Related]
4. New insights into selective PDE4D inhibitors: 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) oxime (GEBR-7b) structural development and promising activities to restore memory impairment.
Brullo C; Ricciarelli R; Prickaerts J; Arancio O; Massa M; Rotolo C; Romussi A; Rebosio C; Marengo B; Pronzato MA; van Hagen BTJ; van Goethem NP; D'Ursi P; Orro A; Milanesi L; Guariento S; Cichero E; Fossa P; Fedele E; Bruno O
Eur J Med Chem; 2016 Nov; 124():82-102. PubMed ID: 27560284
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors.
Brullo C; Massa M; Rocca M; Rotolo C; Guariento S; Rivera D; Ricciarelli R; Fedele E; Fossa P; Bruno O
J Med Chem; 2014 Aug; 57(16):7061-72. PubMed ID: 25126889
[TBL] [Abstract][Full Text] [Related]
6. Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.
Zhou ZZ; Ge BC; Chen YF; Shi XD; Yang XM; Xu JP
Bioorg Med Chem; 2015 Nov; 23(22):7332-9. PubMed ID: 26526739
[TBL] [Abstract][Full Text] [Related]
7. Molecular Bases of PDE4D Inhibition by Memory-Enhancing GEBR Library Compounds.
Prosdocimi T; Mollica L; Donini S; Semrau MS; Lucarelli AP; Aiolfi E; Cavalli A; Storici P; Alfei S; Brullo C; Bruno O; Parisini E
Biochemistry; 2018 May; 57(19):2876-2888. PubMed ID: 29652483
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of novel mouse PDE4D isoforms: molecular cloning, subcellular distribution and detection of isoform-specific intracellular localization signals.
Chandrasekaran A; Toh KY; Low SH; Tay SK; Brenner S; Goh DL
Cell Signal; 2008 Jan; 20(1):139-53. PubMed ID: 18006274
[TBL] [Abstract][Full Text] [Related]
9. A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
Chambers RJ; Abrams K; Castleberry TA; Cheng JB; Fisher DA; Kamath AV; Marfat A; Nettleton DO; Pillar JD; Salter ED; Sheils AL; Shirley JT; Turner CR; Umland JP; Lam KT
Bioorg Med Chem Lett; 2006 Feb; 16(3):718-21. PubMed ID: 16263279
[TBL] [Abstract][Full Text] [Related]
10. Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors.
Hamblin JN; Angell TD; Ballantine SP; Cook CM; Cooper AW; Dawson J; Delves CJ; Jones PS; Lindvall M; Lucas FS; Mitchell CJ; Neu MY; Ranshaw LE; Solanke YE; Somers DO; Wiseman JO
Bioorg Med Chem Lett; 2008 Jul; 18(14):4237-41. PubMed ID: 18539455
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors.
Gökhan-Kelekçi N; Simşek OO; Ercan A; Yelekçi K; Sahin ZS; Işik S; Uçar G; Bilgin AA
Bioorg Med Chem; 2009 Sep; 17(18):6761-72. PubMed ID: 19682910
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of PDE IV inhibitors. First asymmetric synthesis of two of GlaxoSmithKline's highly potent Rolipram analogues.
Zhmurov PA; Sukhorukov AY; Chupakhin VI; Khomutova YV; Ioffe SL; Tartakovsky VA
Org Biomol Chem; 2013 Dec; 11(46):8082-91. PubMed ID: 24169629
[TBL] [Abstract][Full Text] [Related]
13. Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain.
Hirose R; Manabe H; Nonaka H; Yanagawa K; Akuta K; Sato S; Ohshima E; Ichimura M
Eur J Pharmacol; 2007 Nov; 573(1-3):93-9. PubMed ID: 17658510
[TBL] [Abstract][Full Text] [Related]
14. Identification of pyridazino[4,5-b]indolizines as selective PDE4B inhibitors.
Donnell AF; Dollings PJ; Butera JA; Dietrich AJ; Lipinski KK; Ghavami A; Hirst WD
Bioorg Med Chem Lett; 2010 Apr; 20(7):2163-7. PubMed ID: 20202838
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of a novel, orally active PDE4 inhibitor.
Dastidar SG; Ray A; Shirumalla R; Rajagopal D; Chaudhary S; Nanda K; Sharma P; Seth MK; Balachandran S; Gupta N; Palle V
Pharmacology; 2009; 83(5):275-86. PubMed ID: 19321962
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
Gallant M; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Huang Z; Lacombe P; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini J; Masson P; Mastracchio A; Nicholson D; Nicoll-Griffith DA; Perrier H; Salem M; Styhler A; Young RN; Girard Y
Bioorg Med Chem Lett; 2008 Feb; 18(4):1407-12. PubMed ID: 18207397
[TBL] [Abstract][Full Text] [Related]
17. New insights into PDE4B inhibitor selectivity: CoMFA analyses and molecular docking studies.
Guariento S; Bruno O; Fossa P; Cichero E
Mol Divers; 2016 Feb; 20(1):77-92. PubMed ID: 26290462
[TBL] [Abstract][Full Text] [Related]
18. New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3.
Stefane B; Brozic P; Vehovc M; Rizner TL; Gobec S
Eur J Med Chem; 2009 Jun; 44(6):2563-71. PubMed ID: 19237229
[TBL] [Abstract][Full Text] [Related]
19. Rhodanine derivatives as novel inhibitors of PDE4.
Irvine MW; Patrick GL; Kewney J; Hastings SF; MacKenzie SJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):2032-7. PubMed ID: 18304812
[TBL] [Abstract][Full Text] [Related]
20. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
